Glenmark Pharmaceuticals’ subsidiary - Glenmark Pharmaceuticals SA (GPSA) has successfully completed the Phase I trial of GRC 15300, a first-in-class TRPV3 inhibitor for treatment of pain.
GRC 15300 is an inhibitor of the TRPV3 (transient receptor potential cation channel, subfamily V, member 3). This is the first TRPV3 inhibitor which entered clinical trials. Glenmark has completed phase I dosing and analysis of the study data of GRC 15300 in the UK and the drug has been well tolerated with a good pharmacokinetic profile.
Glenmark Pharmaceuticals registered growth of 65.17% in its net profit after tax for the year ended March 31, 2011 at Rs 212.18 crore as compared to Rs 128.46 crore for the previous year. Its total income has increased by 19.43% at Rs 1185.02 crore for the year under review from Rs 992.22 crore in previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: